Title	Enzalutamide efficacy (part 1)
Number of Patients Enrolled	16
Number of Patients Evaluable for Toxicity	16
Number of Patients Evaluated for Efficacy	15
Evaluation Method	RECIST 1.1
Response Assessment CR	n = 0 (0%)
Response Assessment PR	n = 0 (0%)
Response Assessment SD	n = 7 (44%)
Response Assessment PD	n = 8 (50%)
Response Assessment OTHER	n = 1 (6%)
(Median) Duration Assessments PFS	1.76 months, CI: 1.61–3.55
(Median) Duration Assessments OS	7.03 months, CI: 3.55–NR
Outcome Notes	One patient did not complete 80% of dosing in cycle 1 and was replaced for DLT per protocol. The patient clinically deteriorated on study and was evaluable for toxicity and survival but not for response.